Financial Statements — GP
Balance Sheet
(in millions USD)| Metric | FY
2024 | FY
2023 | FY
2022 | FY
2021 | FY
2020 |
|---|
| Cash & Equivalents | 1.15 | 0.60 | 6.89 | 15.21 | 0.45 |
| Inventory | 32.01 | 41.61 | 32.25 | 12.46 | 6.59 |
| Total Current Assets | 36.85 | 54.16 | 43.10 | 32.94 | 8.12 |
| Goodwill | -- | 0.25 | -- | -- | -- |
| Total Non-current Assets* | 8.35 | 9.37 | 6.51 | 6.68 | 5.08 |
| Total Assets | 45.20 | 63.53 | 49.61 | 39.62 | 13.21 |
| Total Current Liabilities | 21.29 | 26.50 | 11.51 | 2.13 | 7.38 |
| Total Non-current Liabilities* | 12.34 | 9.36 | 3.71 | 1.33 | 7.00 |
| Total Liabilities | 33.64 | 35.86 | 15.22 | 3.47 | 14.38 |
| Retained Earnings | (79.02) | (60.79) | (46.36) | (31.63) | (23.85) |
| Total Stockholder Equity | 11.57 | 27.66 | 34.39 | 36.15 | (1.17) |
* Derived from reported values
Income Statement
(in millions USD) (except per-share rows)| Metric | FY
2024 | FY
2023 | FY
2022 | FY
2021 | FY
2020 |
|---|
| Total Revenue | 39.27 | 39.70 | 17.24 | 11.88 | 13.50 |
| Cost of Revenue* | 33.91 | 32.45 | 13.36 | 8.30 | 9.45 |
| Gross Profit | 5.36 | 7.25 | 3.88 | 3.58 | 4.05 |
| Research & Development | 1.81 | 2.09 | 1.38 | 0.94 | 0.97 |
| Total Operating Expenses | 22.16 | 20.54 | 18.06 | 9.58 | 7.28 |
| Operating Income | (17.92) | (14.79) | (14.40) | (7.79) | (4.92) |
| Interest Expense | 1.55 | 1.55 | 0.52 | 1.60 | 2.13 |
| Pretax Income | -- | -- | -- | -- | (5.15) |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | (18.34) | (15.04) | (15.01) | (7.84) | (5.15) |
| Basic EPS | (0.74) | (0.64) | -- | -- | -- |
| Diluted EPS | (0.74) | (0.64) | (0.69) | -- | -- |
* Derived from reported values
Cash Flow Statement
(in millions USD)| Metric | FY
2024 | FY
2023 | FY
2022 | FY
2021 | FY
2020 |
|---|
| Operating Cash Flow | (1.13) | (14.76) | (20.34) | (16.39) | (5.11) |
| Investing Cash Flow | (0.76) | 0.30 | (0.54) | (0.35) | (0.16) |
| Financing Cash Flow | 2.32 | 8.19 | 12.66 | 31.52 | 5.50 |
